Famotidine sales will expand through 2036, with above 98% purity at 72.0% of the purity grade category and tablets at 63.0% of form demand in 2026. The market is estimated at USD 0.9 billion in 2026 and is forecast to record a 5.1% CAGR between 2026 and 2036.